Gilead wins US patent trial over HIV prevention drugs
A federal jury ruled in favor of Gilead on Tuesday in a long-running patent battle over the use of its HIV drugs Truvada and Descovy for pre-exposure prophylaxis (PrEP).
While Truvada and Descovy were initially approved for the treatment of HIV in 2004 and 2016, respectively, they each won approvals years later in the preventative setting. The US filed suit against Gilead in 2019, alleging that the company “ignored CDC’s clear contributions and baselessly denied the validity of CDC’s patents” in growing its PrEP franchise.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.